Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT05605093




Registration number
NCT05605093
Ethics application status
Date submitted
28/10/2022
Date registered
4/11/2022
Date last updated
15/10/2024

Titles & IDs
Public title
Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)
Scientific title
Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor
Secondary ID [1] 0 0
S-217622
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
COVID-19 0 0
Condition category
Condition code
Respiratory 0 0 0 0
Other respiratory disorders / diseases
Infection 0 0 0 0
Other infectious diseases
Infection 0 0 0 0
Studies of infection and infectious agents

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Shionogi Protease Inhibitor (S-217622)
Treatment: Drugs - placebo

Experimental: S-217622 (ensitrelvir) plus standard of care (SOC) - Study investigational agent (ensitrelvir) will be administered as oral tablets with dosing of 375mg (3 tabs) once on Day 0 and 125mg (1 tab) once daily on Days 1-4. All participants will receive the full 5-day course, including those who are discharged from hospitalization prior to Day 4.

Placebo comparator: placebo plus standard of care (SOC) - Study investigational placebo will be administered as oral tablets with dosing of 375mg (3 tabs) once on Day 0 and 125mg (1 tab) once daily on Days 1-4. All participants will receive the full 5-day course, including those who are discharged from hospitalization prior to Day 4.


Treatment: Drugs: Shionogi Protease Inhibitor (S-217622)
S-217622 (ensitrelvir) is an oral anti-SARS-CoV2 PI that does not require ritonavir co-administration The dose is 375/125 (375 mg on Day 0, followed by 125 mg daily on Days 1-4).

Treatment: Drugs: placebo
Placebo is an oral tablet administered once (3 tabs) on Day 0 and once (1 tab) daily on days 1-4, 5-day course.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Days to Recovery Scale assessed over 60 days (DRS-60)
Timepoint [1] 0 0
60 days post-intervention
Secondary outcome [1] 0 0
mortality
Timepoint [1] 0 0
60 days post-treatment
Secondary outcome [2] 0 0
a 3-category ordinal outcome
Timepoint [2] 0 0
60 days post-treatment
Secondary outcome [3] 0 0
time to recovery
Timepoint [3] 0 0
60 days post-treatment
Secondary outcome [4] 0 0
proportion of participants who died or required new invasive mechanical ventilation
Timepoint [4] 0 0
60 days post-treatment

Eligibility
Key inclusion criteria
* Age =18 years.
* Informed consent for trial participation.
* Hospital admission (or boarding in an emergency department or other area awaiting hospital admission) with signs and/or symptoms of a respiratory infection.
* Confirmation of SARS-CoV2 infection by nucleic acid test (NAT) or equivalent non- NAT test [list of approved tests is in the PIM] collected within the prior 14 days.
* Onset of symptoms attributable to SARS-CoV2 infection occurred within 14 days before randomization.
* Hospitalized for the management of COVID-19, with signs and/or symptoms suggestive of lower respiratory tract infection.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* The patient is expected to be discharged from the hospital within the next 24 hours.
* Medical condition other than the acute respiratory infection (and its manifestations) that is likely to result in death within 7 days of randomization.
* Use of a strong CYP3A inducer within 14 days prior to enrollment
* Moribund condition, defined as prior cardiac arrest during this hospitalization and life expectancy less than 48 hours of randomization.
* Patient undergoing comfort care measures only such that treatment focuses on end-of- life symptom management over prolongation of life.
* Expected inability or unwillingness to participate in study procedures.
* In the opinion of the investigator, participation in a trial is not in the best interest of the patient.
* Allergy to investigational agent or vehicle
* Use of a concomitant medication that is contraindicated due to a drug-drug interaction with S-217622
* Moderate to severe hepatic impairment (i.e., Child-Pugh class B or C) or acute liver failure.
* Known estimated glomerular filtration rate (eGRF) <30 mL/min/1.73m 2
* Continuous renal replacement therapy or chronic dialysis
* Current pregnancy
* Current breastfeeding and unwillingness to defer breastfeeding for 30 days after the last dose of investigational agent.
* Women of child-bearing potential who are unwilling to abstain from sexual intercourse with men or practice appropriate contraception through 30 days from the last dose of the investigational agent.
* Men who are unwilling to abstain from sexual intercourse with women of child- bearing potential or to use barrier contraception through 30 days from the last dose of the investigational agent.
* Inability to take investigational agent in tablet form by mouth.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
23/12/2022
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
27/07/2025
Actual
Sample size
Target
1500
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Recruitment hospital [1] 0 0
St. Vincent's Hospital (Site 612-002) - Sydney
Recruitment hospital [2] 0 0
Westmead Hospital (Site 612-058) - Westmead
Recruitment hospital [3] 0 0
Austin Health (612-020) - Heidelberg
Recruitment hospital [4] 0 0
The Alfred Hospital (Site 612-017) - Melbourne
Recruitment postcode(s) [1] 0 0
2010 - Sydney
Recruitment postcode(s) [2] 0 0
2145 - Westmead
Recruitment postcode(s) [3] 0 0
3084 - Heidelberg
Recruitment postcode(s) [4] 0 0
3004 - Melbourne
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Colorado
Country [5] 0 0
United States of America
State/province [5] 0 0
Connecticut
Country [6] 0 0
United States of America
State/province [6] 0 0
District of Columbia
Country [7] 0 0
United States of America
State/province [7] 0 0
Florida
Country [8] 0 0
United States of America
State/province [8] 0 0
Illinois
Country [9] 0 0
United States of America
State/province [9] 0 0
Indiana
Country [10] 0 0
United States of America
State/province [10] 0 0
Kansas
Country [11] 0 0
United States of America
State/province [11] 0 0
Kentucky
Country [12] 0 0
United States of America
State/province [12] 0 0
Maryland
Country [13] 0 0
United States of America
State/province [13] 0 0
Massachusetts
Country [14] 0 0
United States of America
State/province [14] 0 0
Michigan
Country [15] 0 0
United States of America
State/province [15] 0 0
Minnesota
Country [16] 0 0
United States of America
State/province [16] 0 0
Mississippi
Country [17] 0 0
United States of America
State/province [17] 0 0
Missouri
Country [18] 0 0
United States of America
State/province [18] 0 0
Nebraska
Country [19] 0 0
United States of America
State/province [19] 0 0
New Hampshire
Country [20] 0 0
United States of America
State/province [20] 0 0
New Jersey
Country [21] 0 0
United States of America
State/province [21] 0 0
New Mexico
Country [22] 0 0
United States of America
State/province [22] 0 0
New York
Country [23] 0 0
United States of America
State/province [23] 0 0
North Carolina
Country [24] 0 0
United States of America
State/province [24] 0 0
Ohio
Country [25] 0 0
United States of America
State/province [25] 0 0
Oregon
Country [26] 0 0
United States of America
State/province [26] 0 0
Pennsylvania
Country [27] 0 0
United States of America
State/province [27] 0 0
Rhode Island
Country [28] 0 0
United States of America
State/province [28] 0 0
South Carolina
Country [29] 0 0
United States of America
State/province [29] 0 0
South Dakota
Country [30] 0 0
United States of America
State/province [30] 0 0
Tennessee
Country [31] 0 0
United States of America
State/province [31] 0 0
Texas
Country [32] 0 0
United States of America
State/province [32] 0 0
Utah
Country [33] 0 0
United States of America
State/province [33] 0 0
Virginia
Country [34] 0 0
United States of America
State/province [34] 0 0
Washington
Country [35] 0 0
United States of America
State/province [35] 0 0
West Virginia
Country [36] 0 0
United States of America
State/province [36] 0 0
Wisconsin
Country [37] 0 0
Argentina
State/province [37] 0 0
Buenos Aires
Country [38] 0 0
Argentina
State/province [38] 0 0
Cordoba
Country [39] 0 0
Argentina
State/province [39] 0 0
Santa Fe
Country [40] 0 0
Brazil
State/province [40] 0 0
SP
Country [41] 0 0
Denmark
State/province [41] 0 0
N
Country [42] 0 0
Denmark
State/province [42] 0 0
Aalborg
Country [43] 0 0
Denmark
State/province [43] 0 0
Copenhagen
Country [44] 0 0
Denmark
State/province [44] 0 0
Hellerup
Country [45] 0 0
Denmark
State/province [45] 0 0
Hillerød
Country [46] 0 0
Denmark
State/province [46] 0 0
Hvidovre
Country [47] 0 0
Denmark
State/province [47] 0 0
Kolding
Country [48] 0 0
Denmark
State/province [48] 0 0
Odense
Country [49] 0 0
Denmark
State/province [49] 0 0
Roskilde
Country [50] 0 0
Georgia
State/province [50] 0 0
Tbilisi
Country [51] 0 0
Germany
State/province [51] 0 0
Bonn
Country [52] 0 0
Germany
State/province [52] 0 0
Cologne
Country [53] 0 0
Germany
State/province [53] 0 0
Frankfurt
Country [54] 0 0
Greece
State/province [54] 0 0
Attica
Country [55] 0 0
Greece
State/province [55] 0 0
Evros
Country [56] 0 0
Japan
State/province [56] 0 0
Aichi
Country [57] 0 0
Japan
State/province [57] 0 0
Tokyo
Country [58] 0 0
Japan
State/province [58] 0 0
Osaka
Country [59] 0 0
Korea, Republic of
State/province [59] 0 0
Gyeonggi
Country [60] 0 0
Korea, Republic of
State/province [60] 0 0
Seoul
Country [61] 0 0
Nigeria
State/province [61] 0 0
FCT
Country [62] 0 0
Poland
State/province [62] 0 0
Warsaw
Country [63] 0 0
Puerto Rico
State/province [63] 0 0
San Juan
Country [64] 0 0
Singapore
State/province [64] 0 0
Singapore
Country [65] 0 0
South Africa
State/province [65] 0 0
KwaZulu-Natal
Country [66] 0 0
South Africa
State/province [66] 0 0
Western Cape
Country [67] 0 0
Spain
State/province [67] 0 0
Barcelona
Country [68] 0 0
Spain
State/province [68] 0 0
Madrid
Country [69] 0 0
Switzerland
State/province [69] 0 0
Zurich
Country [70] 0 0
Thailand
State/province [70] 0 0
Bangkok
Country [71] 0 0
Thailand
State/province [71] 0 0
Khon Kaen
Country [72] 0 0
Uganda
State/province [72] 0 0
Entebbe
Country [73] 0 0
Uganda
State/province [73] 0 0
Gulu
Country [74] 0 0
Uganda
State/province [74] 0 0
Kampala
Country [75] 0 0
Uganda
State/province [75] 0 0
Lira
Country [76] 0 0
Uganda
State/province [76] 0 0
Masaka
Country [77] 0 0
Ukraine
State/province [77] 0 0
Frankivs'k
Country [78] 0 0
United Kingdom
State/province [78] 0 0
London
Country [79] 0 0
United Kingdom
State/province [79] 0 0
Newcastle Upon Tyne

Funding & Sponsors
Primary sponsor type
Other
Name
University of Minnesota
Address
Country
Other collaborator category [1] 0 0
Government body
Name [1] 0 0
National Institute of Allergy and Infectious Diseases (NIAID)
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
Treatments are needed to improve outcomes among patients hospitalized for COVID-19, including direct-acting antiviral (DAA) agents to mitigate the pathology driven by ongoing viral replication. This trial will evaluate S-217622 (ensitrelvir), an anti-SARS-CoV2 3C-like protease inhibitor (PI) developed by Shionogi \&; Co. Ltd.

The study design is a randomized, placebo-controlled, multi-center international clinical trial that will evaluate the clinical efficacy of ensitrelvir when given in addition to standard of care (SOC) for inpatients with COVID-19. The SOC will be determined by local established guidelines and may include additional DAA (e.g., remdesivir) and immunomodulatory treatment strategies. Certain SOC treatments will be pre-specified prior to randomization.
Trial website
https://clinicaltrials.gov/study/NCT05605093
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Jens Lundgren, PhD
Address 0 0
University of Copenhagen
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Cavan Reilly, PhD
Address 0 0
Country 0 0
Phone 0 0
612-624-9644
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT05605093